CA1192961A - Rate adaptive demand pacemaker - Google Patents
Rate adaptive demand pacemakerInfo
- Publication number
- CA1192961A CA1192961A CA000416050A CA416050A CA1192961A CA 1192961 A CA1192961 A CA 1192961A CA 000416050 A CA000416050 A CA 000416050A CA 416050 A CA416050 A CA 416050A CA 1192961 A CA1192961 A CA 1192961A
- Authority
- CA
- Canada
- Prior art keywords
- escape interval
- rate
- demand
- bit
- physiological parameter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/362—Heart stimulators
- A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
- A61N1/36514—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure
- A61N1/36557—Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure controlled by chemical substances in blood
Abstract
ABSTRACT OF THE DISCLOSURE
An implantable pacer having an effective stimulation rate which varies in response to a measured physiological parameter. Changes in the parameter to be measured must be related to physiologically required changes in heart rate. The level of oxygen within intracardiac or pulmonary artery venous blood is the preferred parameter. This parameter is measured by an oxygen sensor located on a transvenously implanted lead. As with normal demand pacers, a sensing electrode, also located on the lead, provides the pacer with an indication of whether a pacing pulse must be generated.
The measured physiological parameter determines the escape interval for demand pacing. As such, a given minimum rate is determined for a given level of molecular oxygen in the intracardiac or pulmonary artery venous blood. The technique is readily employed in both ventricular and atrial-ventricular sequential modes.
An implantable pacer having an effective stimulation rate which varies in response to a measured physiological parameter. Changes in the parameter to be measured must be related to physiologically required changes in heart rate. The level of oxygen within intracardiac or pulmonary artery venous blood is the preferred parameter. This parameter is measured by an oxygen sensor located on a transvenously implanted lead. As with normal demand pacers, a sensing electrode, also located on the lead, provides the pacer with an indication of whether a pacing pulse must be generated.
The measured physiological parameter determines the escape interval for demand pacing. As such, a given minimum rate is determined for a given level of molecular oxygen in the intracardiac or pulmonary artery venous blood. The technique is readily employed in both ventricular and atrial-ventricular sequential modes.
Description
~3~
The present invention relates generally to medical devices, and more specifically relates to implanta~lc electronic devices for muscle stimulation.
The earliest implantable pacing systems operate asynchronously to normal physiologic functions. United States Patent No. 3,057,356, issued to Greatbatch on October 9, 1962 teaches such a pacer wh;ch has a fixed rate oscillator coupled to an output dri~er circuit, Each cycle of the fixed rate oscillator causes generation of a stimulating pulse by the output driver circuit. Designs soon incorporated the demand feature which senses natural electrical activity in the heart and generates a stimulating pulse only if none is provided physiologically within a fixed escapement period. Demand mode pacers are now the most popular and probably outnumber all other types combined. Even though later improvements provide programm-ability of the escape interval, the effective pacing rate of such demand pacers is non-responsive to changes in physiological requirements.
There has been considerable work done in the area of physiologically controlled pacers. Mos~ of these devices measure some parameter and adjust the period of the oscillator in response to changes therein. An early such device is taught by Cohen in United States Patent No.3,358,690 issued December 19, 1967, In this special case~ however, the physiologic parameter measured is instantaneous blood pressure within the right atrium. This system will apparently work well for patients having complete atrial ventricular block with properly paced atria. The Cohen approach is not likely to be effective for sick sinus syndrome, sinus/atrial block, or similar disorders.
Later physiologically controlled pacer systems have been ~k developed which have more general appllcation and may be categorized by the parameter measured. Krasner et al in United States Patent No. 3,593,718, issued July ~0, 1971~ teaches sensillg of mechanical activity within the thorax. It is assumed that changes in respiration rate are thereby sensed.
The oscillator of the pacing system has its rate controlled by changes in this parameter. ~ahl, in United States Patent No. 4,140,132,issued February 20, 1979, teaches an improved implantable sensor for determining level of a patient's physical activity for rate-controlling a pacer as taught by Krasner et al, Bozal Gonzalez in United States Patent No. 4,201,219~ issued May 6, lg80, teaches rate control of a pacer based upon neurological activity.
Electrodes imbedded in the nervous system sense electrical activity. Somehow, the amount of this elec-trical activity is used to control the oscillator rate of an asynchronous pacer.
By far the most promising techniques appear to involve the sensing of csrtain chemical parameters of venous, often intracardiac blood. Alcidi in United States Patent No. 4,009,721,issued March 1, 1977, teaches a pacer controlled by the pH of the blood. A chronically implantable sensor determines the blood pH. The rate of an oscillator of an asynchronous pacer is controlled by the sensed pH. It has been shown that blood pH decreases during prolonged muscular exercise. Mauer et al in United States Patent No, 4,252,124,issued February 24, 1981, teach an improved pH sensor.
Wirtzfeld et al in United S~ates Patent No. 4,2023339, issued May 13J 1980, teach a pacing system having the rate of an asynchronous oscillator controlled by the 2 level of the intracardiac venous blood, As with all kno~m prior art, physiologically controlled pacers~ Wirtzfeld et al ~9;~
teach ~hat is essentially an asynchronous pacer as described by the above identified patent issued to Greatbatch~ with an oscillator rate directly controlled by the measured parameter. As such, these devices are less than optimal for treating cases of partial heart block.
The present invention employs demand mode pacing with an escape interv~l that is determined by a measured physiological parameter. This results in a pacer system which can intermittently pace, upon demand, in hearts with partial bloc~ or sick sinus syndrome at a min; lm rate that varies with physiological requirements. The preferred mode senses level of molecular oxygen within intracardiac venous blood. As the oxygen level decreases, the escape interval is shortened thus providing a higher m;nir~ rate. Similarly, an increase in oxygen level causes a lengthened escape interval. Notice that, unlike prior art physiologically controlled pacers, the present invention treats partial heart block or sick sinus syndrome in the demand mode.
The present invention may be readily employed with sensors which measure other parameters, such as pH of blood, respiration rate, etc. Also, the presen~ invention is readily utilized in both single chamber and two-chamber pacing modes.
Thus, in accordance with one broad aspect of the invention, there is provided a body implantable stimulator for body tissue comprising:
means for measuring a physiological parameter;
means for monitoring electrical activity in said body tissues means responsively coupled to said measuring means for computing a variable time interval based upon said physiological parameter as measured by said measuring means; and means responsively coupled to said monitoring means and said - 3 ~
computing means for generating an electrical stimulation pulse if said monitoring means does not sense a predetermined elec~rical event during said variable time interval.
In accordance with another broad aspect of the invention there is provided a demand heart pacemaker for providing stimulating pulses to the heart at a predetermined rate in the absence of naturally occurring heartbeats comprising:
sensing means for sensing naturally occurring heart signals and generating a reset signal;
pulse generator means for generating stimulating pulses at a min;r~lm pacing rate, including timing means for providing each stimulating pulse separated by an escape interval corresponding to the pacing rate and reset means responsive to a reset signal for resetting said timing means and restarting the escape interval;
means for measuring a physiological parameter indicative oE the level of cardiac output demanded by the patient's body and for providing an escape interval modifying signal; and means responsive to the escape interval modifying signal for adjusting the escape interval to provide pacing pulses on demand at a m;n;mllm rate correlated to the cardiac output requirements of the patient.
~RIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a schematic diagram of a typical prior art physiologically controlled pacing system.
Figure 2 is a schematic diagram of a single chamber pacing system employing the present invention.
Figure 3 is a schematic diagram of Demand Logic 106.
Figure ~l is a schematic diagram of Sensor Processing 30.
Figure 5 is a schematic diagram of the dual-chamber pacing system employing the present invention.
Figure 6a is a table relating shit register position and corresponding minim~lm heart rate.
Figure 6b is a table relating oxygen level to escape interval.
The present invention is described herein in relation to the preferred modes of sing'e and t~o-chamber pacing systems employing sensors measuring molecular oxygen level in intracardiac venous blood. Those of skill in the art, however, will be readily able to apply these teachings to devices using other pacing modes and measuring other physiologic parameters.
Figure 1 is a schematic diagram of a typical prior art physiologically controlled pacing system. Sensor 12 is located within right ventricle 20 of heart 10. Sensor 12 may measure molecular oxygen level in the intracardiac blood as taught by Wirtzel~eld et al, for example, Line 14 transmits the output of Sensor 12 to Sensor processing 30 of pulse generator 2~. Sensor processing 30 transforms the sensed signal into a signal for controlling the rate of variable rate oscillator 28 via line 32.
The output of variable rate oscillator 28 is thus a train of pulses having an interpulse period determined by the sensed parameter. Driver 26 amplifies this pulse train which is transferred to stimulating electrode 18 via conductor 16, Thus, right ventricle 20 is stimulated asynchronously of atrium 22 at a rate determined by the levei of oxygen sensed by Sensor 12.
Figure 2 is a schematic diagram of a single chamber pacing system employing the present invention. The system employs a prior art sensor 12 located within right ventricle 20 of heart 10. A probe for measuring oxygen level as disclosed in the Nirtzfeld et al patent is preferable, However~
the readcr should acqllaint hi~self ~ith the papers: "A Miniature Fiber Optic p~l Sensor Suitable for In-~ivo Application," by Goldstein et al of the National Institute of Health and ~Fiber Optic pH Probe for Physiological Use~"
Anal~tical Chemistry, Volume 52, pp ~64-869 ~1980) by Peterson et al. Though these papers describe devices for measuring the less desirable parameter of p~, the technique of indirect measurement the~ propose seems promising for chronically implantable oximetry sensors as well. Sensor processing 30 converts the analog signal received from sensor 12 via line 14 into digital form and transfers a digital escape interval control signal to demand logic 106 via line 32.
Line 104 transfers an intracardiac EKG signal from right ventricle 20 to sense amp 102, The operation of sense amp 102 is common in the art, Its purpose is to examine the intracardiac EKG signal received via line 104 and determine when a QRS complex of natural origin is sensed. The output of sense amp 102 via line 108 signifies that no artificial stimulation pulse should be generated for at least one complete escape interval~ since a naturally paced contraction has just occurred, United States Patent No, 3,478~746 issued to Greatbatch teaches the function and operation of such a sense amplifier, Fixed rate oscillator 112 serves as an internal clock for demand logic 106, A rate of 60 hertz is chosen as sufficiently fast and yet conserving of po~er. Fixed rate oscillator 112 supplies a 60 hertz pulse train to demand logic 106 via line 110.
Demand logic 106 counts an escape interval having a period - established by sensor processing 30 in multiples of 1/60 second, If a pulse ~ .
is not rec~ived fl~om sense amp 102 via line 108 during that escape interval, demand logic 106 transfers a pulse enable signal to driver 26 via line 34.
If a pulse is received from sense amp 102, a naturally paced contraction has occurred and the escape interval is reset without transferring a pulse enable signal to driver 26 via line 34. The important feature is that the escape interval is not fixed but is a period determined by -the sign~l received from sensor processing 30 via line 32 which is indicative of the current oxygen level in the intracardiac blood.
Driver 26 receives the pulse enable signal from demand logic 106 via line 34 and produces a stimulation pulse which is transferred to the tissue of right ventricle 20 by conductor 16 and electrode 18. Driver 26 is preferably a capaci~ive discharge circuit common in the art. The design of such a circuit may be found in commonly assigned United States Patent No. 4,276,883 iss~led to McDonald et al.
Figure 3 is a detailed schematic diagram of demand logic 106.
The function of demand logic 106 is to count a period of time equivalent to the escape interval for the current level of oxygen in the intracardiac blood and generate a pulse enable signal if and only if no QRS complex was detected during that escape interval. Upon generation o~ a pulse enable or receipt of a QRS complex detection signal, the escape interval is reset to zero.
The clock signal is a 60 hertz pulse train received from fixed rate oscillator 112 via line 110 as explained above. The clock signal serves to sequence 30 bit shift register 156 and 38 bit shift register 158. These are cons~ructed from common CMOS monolithic par~ types.
OR gate 150 outputs a start reset signal whenever a QRS detect signal is received from sense amp 102 via line 108 or a pulse enable signal is generated and transmitted to OR gate 150 via line 34a. One-shot 152, being a co~llon part type forms the start reset signal into a clear signal suitable for clearing JO bit shift register 156 and 38 bit shift register 158.
The output of one-shot 152 supplies the clear signal via lines 168a and 168b to 30 bit shift register 156 and 38 bit shift register 158, respectively.
The clear signal generated by one-shot 152 is also transferred to delay 154 which delays the pulse sufficiently long to enable 3O bit shif~
register 156 and 38 bit shift register 158 to be cleared. The pulse width of the clear signal is a sufficient delay time. The output of delay 154 is transferred via line 170 to set the least significant bit (LSB) position of 30 bit shift register 156. The result is that 30 bit shift register 156 and 38 bit shift register 158 are both cleared at the occurrence of a sensed QRS complex or the generation of a stimulating pulse. The LSB is next set and shifted one bit position at each pulse of the clock signal li.e., at 60 hert~). It is easily seen that the LSB requires 500 milliseconds to shift to the carry output of 30 bit shift register 156 from whence it is propagated via line 166 to the LSB position of 38 bit shift register 158. Again, it requires 1/60 second to shift to each succeeding bit position of 38 bit shift register 158.
It would take an additional 633 milliseconds for the set bit to shift the entire length of 38 bit shift register 158. This provides a total time of 1,133 seconds to shift the entire combined length of 30 bit shift register 156 and 38 bit shift register 158. The m~ximllm escape interval for the system is therefore 1,133 seconds, which corresponds to a heart rate of 52.9 beats per minute.
The output of each of thc 3S bit positions of 38 bit shift register 158 is supplied via cable 16~ to 3S x 1 ~IUX 162. By selecting the desired one of the 38 bit positions any one of 38 different escape intervals may be provided between 500 milliseconds (corresponding -to 120 beats per minute) and 1.133 milliseconds ~corresponding to 52.9 beats per minute) in 1/60 second intervals. Of course, the rate of the clock signal may be increased to achieve greater resolution if required. Similarly, the length of 38 bit shift register 158 may be changed and/or the length of 30 bit shift register 156 changed to change the range of selectable escape intervals.
Common monolithic CMOS parts are used to fabricate 38 x 1 MUX 162.
A six bit inpu~ received from six bit latch 160 via line 161 selects one of the 38 bit positions of 38 blt shift register 158 and thus determines the escape interval. If the LSB entered into 30 bit shift register 156 reaches the selected one of the 38 bit positions of 38 bit shift register 158, 38 x 1 MUX
162 outputs the pulse enable signal via line 34. Referring again to Figure 2, it is seen that this results in the output of a stimulating pulse by driver 26.
To ensure a m;n; Im rate based upon the r~ escape interval~ the carry output of 38 bit shift register 158 may be "ORED" wi~h line 3~. ~his is an optional safety measure.
Referring again to Figure 3, selection by 38 x 1 MUX 162 is made by the six bit contents of six bit latch 160 which simply holds the current escape interval selector as received from sensor processing 30. A single common monolithic CMOS part is available to implement six bit latch 160.
Two control signals are required by six bit latch 160 as received by cable 32a. A first one of these signals clears the contents of six bit _ g _ 3~
latch 160 ancl a seconcl one is delayed and enables *he six bit quantity on cable 32b to be latched into six bit latch 160.
Figure 4 is a detailed schematic view of sensor processing 30.
The analog sensor information is received from sensor 12 via line 14. ~s in ~Yirt7feld et al. this is simply a signal having a voltage that is proportional to the percentage of concentration of molecular oxygen in the intraca-rdiac venous blood. Amp 172 processes the analog signal and scales it for input to six bit A/D 176 via line 182~ The processed analog signal is converted by six bit A/D 176 into a digital signal which is transmitted via cable 32b to six bit latch 160. The data ready output signal is supplied via one conductor of cable 32a to clear six bit latch 160. The data ready signal is delayed by delay 178 and sent vi,a the other conductor of cable 32a to enable the six bit data into six bit latch 160. Clock 174 supplies the convert signal to six bit A/D 176. Clock 174 may have a very low rate (i.e.l a fraction of one hertz) as the measurable changes in blood oxygen level occur slowly relative to the conversion time of six bit A/D 176 and the resulting escape interval. ~ixed rate oscillator 112 or a submultiple thereof may be substituted for clock 174, but the asynchrony of a separate clock 174 is probably not detrimental and requires fewer components.
Figure 5 is an alternate embodiment of the present invention as incorporated in a two-chamber pacing system. The elements o~ sensor processing 30, sensor 12, electrode 18, demand logic 106 and fixed rate oscillator 112 are identical to the corresponding elements of the single chamber system and function as discussed above. Driver (v) 26 is also identical to the driver 26 of the single chamber system.
Sense amp 102 of the single chamber systeni is replaced by sense J~
amp ~p) 102a l~hich is coupled via line 104a to an electrode in atrium 22. In this way sense amp 102a monitors the atrial activity rather than the ventricular activity mollitored by sense amp 102 in the single chamber system ~see also Figure 2). ThereforeJ sense amp 102a (p) generates a p-wave sensed signal which is transferred to demand logic 106 via line 108~ whenever atrium 22 is naturally paced. Sense amp ~p) 102a is similar to sense amp 102 except for the enhanced sensitivity as is commonly known in the art for p-wave sense amplifiers.
As with the single chamber system~ demand logic 106 generates a pulse enab.e signal whenever the escape interval period has been reached as explained above. However, in this embodiment, the escape interval is measured between p-waves rather than between r-waves. Therefore a delay is supplied by A-V delay 202 to stimulate the normal atrial-to-ventricular propagation delay. This may be a fixed delay which is easily accomplished or may be a delay which is related to the pacing rate ~i.e., the inverse of the escape interval) as is also known in the art, Atrium 22 may also be artifically stimulated using driver ~A) 204 and conductor 206. This option provides an effective therapy for combined intermittent sinus-atrial block, sick sinus syndrome, sinus bradycardia, and atrial-ventricular block. The optional driver ~A) 204 improves hemodynamic performance by stimulating a synchronized atrial kick.
Other configurations can be readily constructed using the teachings found herein. For example, driver ~V) 26 may be deleted with only driver ~A) 204 in use. This configuration would readily treat intermittent sinus-atrial block or sick sinus syndrome in a patient having normal atrial-ventricular conduction.
Figure 6a is a table showing the effective mini 1~ heart rate in beats per minute correspond;ng to various selectecl bit positions of 30 bit shift register 156 and 38 bit shift register 158 ~with the total cumulative number of bit positions shown). The m~ m number of bit positions permitted by the embodiment of demand logic 106 shown in Figure 3 is 68. However, the table of Figure 6a is extended to 78 bit positions to show the e-ffect of extending 3~ bit shift register 158 to ~8 bits.
Figure 6b shows the relationship between a given level of molecular oxygen in the intracardiac venous blood and the output required of six bit A/D
176 to six bit latch 160. This result is obtained by adjusting the bias of amp 172 to provide a zero voltage input to six bit A/D 176 for an oxygen level of 60% of saturation. The gain of amp 172 is adjusted to drive six bit A/D
176 to approximately one-half of its m~imllm value for an oxygen level o-f 70% of saturation. As can be seen, therefore, a five bit A/D conversion is sufficient for the chosen system resolution~ However~ six bit devices are more commonly available. The total measured range of interest in oxygen level is between 60% and 70%. Because of the components chosen, this provides an escape interval range corresponding to 52.~ to 120 beats per minute. The system is self-limiting to remain within this range. The ideal relationship of saturation levels to escape interval can vary from patient to patient, and is preferably programmable using an external device. Support may be readily found in the current literature to permit determination of other effective relationships.
The present invention relates generally to medical devices, and more specifically relates to implanta~lc electronic devices for muscle stimulation.
The earliest implantable pacing systems operate asynchronously to normal physiologic functions. United States Patent No. 3,057,356, issued to Greatbatch on October 9, 1962 teaches such a pacer wh;ch has a fixed rate oscillator coupled to an output dri~er circuit, Each cycle of the fixed rate oscillator causes generation of a stimulating pulse by the output driver circuit. Designs soon incorporated the demand feature which senses natural electrical activity in the heart and generates a stimulating pulse only if none is provided physiologically within a fixed escapement period. Demand mode pacers are now the most popular and probably outnumber all other types combined. Even though later improvements provide programm-ability of the escape interval, the effective pacing rate of such demand pacers is non-responsive to changes in physiological requirements.
There has been considerable work done in the area of physiologically controlled pacers. Mos~ of these devices measure some parameter and adjust the period of the oscillator in response to changes therein. An early such device is taught by Cohen in United States Patent No.3,358,690 issued December 19, 1967, In this special case~ however, the physiologic parameter measured is instantaneous blood pressure within the right atrium. This system will apparently work well for patients having complete atrial ventricular block with properly paced atria. The Cohen approach is not likely to be effective for sick sinus syndrome, sinus/atrial block, or similar disorders.
Later physiologically controlled pacer systems have been ~k developed which have more general appllcation and may be categorized by the parameter measured. Krasner et al in United States Patent No. 3,593,718, issued July ~0, 1971~ teaches sensillg of mechanical activity within the thorax. It is assumed that changes in respiration rate are thereby sensed.
The oscillator of the pacing system has its rate controlled by changes in this parameter. ~ahl, in United States Patent No. 4,140,132,issued February 20, 1979, teaches an improved implantable sensor for determining level of a patient's physical activity for rate-controlling a pacer as taught by Krasner et al, Bozal Gonzalez in United States Patent No. 4,201,219~ issued May 6, lg80, teaches rate control of a pacer based upon neurological activity.
Electrodes imbedded in the nervous system sense electrical activity. Somehow, the amount of this elec-trical activity is used to control the oscillator rate of an asynchronous pacer.
By far the most promising techniques appear to involve the sensing of csrtain chemical parameters of venous, often intracardiac blood. Alcidi in United States Patent No. 4,009,721,issued March 1, 1977, teaches a pacer controlled by the pH of the blood. A chronically implantable sensor determines the blood pH. The rate of an oscillator of an asynchronous pacer is controlled by the sensed pH. It has been shown that blood pH decreases during prolonged muscular exercise. Mauer et al in United States Patent No, 4,252,124,issued February 24, 1981, teach an improved pH sensor.
Wirtzfeld et al in United S~ates Patent No. 4,2023339, issued May 13J 1980, teach a pacing system having the rate of an asynchronous oscillator controlled by the 2 level of the intracardiac venous blood, As with all kno~m prior art, physiologically controlled pacers~ Wirtzfeld et al ~9;~
teach ~hat is essentially an asynchronous pacer as described by the above identified patent issued to Greatbatch~ with an oscillator rate directly controlled by the measured parameter. As such, these devices are less than optimal for treating cases of partial heart block.
The present invention employs demand mode pacing with an escape interv~l that is determined by a measured physiological parameter. This results in a pacer system which can intermittently pace, upon demand, in hearts with partial bloc~ or sick sinus syndrome at a min; lm rate that varies with physiological requirements. The preferred mode senses level of molecular oxygen within intracardiac venous blood. As the oxygen level decreases, the escape interval is shortened thus providing a higher m;nir~ rate. Similarly, an increase in oxygen level causes a lengthened escape interval. Notice that, unlike prior art physiologically controlled pacers, the present invention treats partial heart block or sick sinus syndrome in the demand mode.
The present invention may be readily employed with sensors which measure other parameters, such as pH of blood, respiration rate, etc. Also, the presen~ invention is readily utilized in both single chamber and two-chamber pacing modes.
Thus, in accordance with one broad aspect of the invention, there is provided a body implantable stimulator for body tissue comprising:
means for measuring a physiological parameter;
means for monitoring electrical activity in said body tissues means responsively coupled to said measuring means for computing a variable time interval based upon said physiological parameter as measured by said measuring means; and means responsively coupled to said monitoring means and said - 3 ~
computing means for generating an electrical stimulation pulse if said monitoring means does not sense a predetermined elec~rical event during said variable time interval.
In accordance with another broad aspect of the invention there is provided a demand heart pacemaker for providing stimulating pulses to the heart at a predetermined rate in the absence of naturally occurring heartbeats comprising:
sensing means for sensing naturally occurring heart signals and generating a reset signal;
pulse generator means for generating stimulating pulses at a min;r~lm pacing rate, including timing means for providing each stimulating pulse separated by an escape interval corresponding to the pacing rate and reset means responsive to a reset signal for resetting said timing means and restarting the escape interval;
means for measuring a physiological parameter indicative oE the level of cardiac output demanded by the patient's body and for providing an escape interval modifying signal; and means responsive to the escape interval modifying signal for adjusting the escape interval to provide pacing pulses on demand at a m;n;mllm rate correlated to the cardiac output requirements of the patient.
~RIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a schematic diagram of a typical prior art physiologically controlled pacing system.
Figure 2 is a schematic diagram of a single chamber pacing system employing the present invention.
Figure 3 is a schematic diagram of Demand Logic 106.
Figure ~l is a schematic diagram of Sensor Processing 30.
Figure 5 is a schematic diagram of the dual-chamber pacing system employing the present invention.
Figure 6a is a table relating shit register position and corresponding minim~lm heart rate.
Figure 6b is a table relating oxygen level to escape interval.
The present invention is described herein in relation to the preferred modes of sing'e and t~o-chamber pacing systems employing sensors measuring molecular oxygen level in intracardiac venous blood. Those of skill in the art, however, will be readily able to apply these teachings to devices using other pacing modes and measuring other physiologic parameters.
Figure 1 is a schematic diagram of a typical prior art physiologically controlled pacing system. Sensor 12 is located within right ventricle 20 of heart 10. Sensor 12 may measure molecular oxygen level in the intracardiac blood as taught by Wirtzel~eld et al, for example, Line 14 transmits the output of Sensor 12 to Sensor processing 30 of pulse generator 2~. Sensor processing 30 transforms the sensed signal into a signal for controlling the rate of variable rate oscillator 28 via line 32.
The output of variable rate oscillator 28 is thus a train of pulses having an interpulse period determined by the sensed parameter. Driver 26 amplifies this pulse train which is transferred to stimulating electrode 18 via conductor 16, Thus, right ventricle 20 is stimulated asynchronously of atrium 22 at a rate determined by the levei of oxygen sensed by Sensor 12.
Figure 2 is a schematic diagram of a single chamber pacing system employing the present invention. The system employs a prior art sensor 12 located within right ventricle 20 of heart 10. A probe for measuring oxygen level as disclosed in the Nirtzfeld et al patent is preferable, However~
the readcr should acqllaint hi~self ~ith the papers: "A Miniature Fiber Optic p~l Sensor Suitable for In-~ivo Application," by Goldstein et al of the National Institute of Health and ~Fiber Optic pH Probe for Physiological Use~"
Anal~tical Chemistry, Volume 52, pp ~64-869 ~1980) by Peterson et al. Though these papers describe devices for measuring the less desirable parameter of p~, the technique of indirect measurement the~ propose seems promising for chronically implantable oximetry sensors as well. Sensor processing 30 converts the analog signal received from sensor 12 via line 14 into digital form and transfers a digital escape interval control signal to demand logic 106 via line 32.
Line 104 transfers an intracardiac EKG signal from right ventricle 20 to sense amp 102, The operation of sense amp 102 is common in the art, Its purpose is to examine the intracardiac EKG signal received via line 104 and determine when a QRS complex of natural origin is sensed. The output of sense amp 102 via line 108 signifies that no artificial stimulation pulse should be generated for at least one complete escape interval~ since a naturally paced contraction has just occurred, United States Patent No, 3,478~746 issued to Greatbatch teaches the function and operation of such a sense amplifier, Fixed rate oscillator 112 serves as an internal clock for demand logic 106, A rate of 60 hertz is chosen as sufficiently fast and yet conserving of po~er. Fixed rate oscillator 112 supplies a 60 hertz pulse train to demand logic 106 via line 110.
Demand logic 106 counts an escape interval having a period - established by sensor processing 30 in multiples of 1/60 second, If a pulse ~ .
is not rec~ived fl~om sense amp 102 via line 108 during that escape interval, demand logic 106 transfers a pulse enable signal to driver 26 via line 34.
If a pulse is received from sense amp 102, a naturally paced contraction has occurred and the escape interval is reset without transferring a pulse enable signal to driver 26 via line 34. The important feature is that the escape interval is not fixed but is a period determined by -the sign~l received from sensor processing 30 via line 32 which is indicative of the current oxygen level in the intracardiac blood.
Driver 26 receives the pulse enable signal from demand logic 106 via line 34 and produces a stimulation pulse which is transferred to the tissue of right ventricle 20 by conductor 16 and electrode 18. Driver 26 is preferably a capaci~ive discharge circuit common in the art. The design of such a circuit may be found in commonly assigned United States Patent No. 4,276,883 iss~led to McDonald et al.
Figure 3 is a detailed schematic diagram of demand logic 106.
The function of demand logic 106 is to count a period of time equivalent to the escape interval for the current level of oxygen in the intracardiac blood and generate a pulse enable signal if and only if no QRS complex was detected during that escape interval. Upon generation o~ a pulse enable or receipt of a QRS complex detection signal, the escape interval is reset to zero.
The clock signal is a 60 hertz pulse train received from fixed rate oscillator 112 via line 110 as explained above. The clock signal serves to sequence 30 bit shift register 156 and 38 bit shift register 158. These are cons~ructed from common CMOS monolithic par~ types.
OR gate 150 outputs a start reset signal whenever a QRS detect signal is received from sense amp 102 via line 108 or a pulse enable signal is generated and transmitted to OR gate 150 via line 34a. One-shot 152, being a co~llon part type forms the start reset signal into a clear signal suitable for clearing JO bit shift register 156 and 38 bit shift register 158.
The output of one-shot 152 supplies the clear signal via lines 168a and 168b to 30 bit shift register 156 and 38 bit shift register 158, respectively.
The clear signal generated by one-shot 152 is also transferred to delay 154 which delays the pulse sufficiently long to enable 3O bit shif~
register 156 and 38 bit shift register 158 to be cleared. The pulse width of the clear signal is a sufficient delay time. The output of delay 154 is transferred via line 170 to set the least significant bit (LSB) position of 30 bit shift register 156. The result is that 30 bit shift register 156 and 38 bit shift register 158 are both cleared at the occurrence of a sensed QRS complex or the generation of a stimulating pulse. The LSB is next set and shifted one bit position at each pulse of the clock signal li.e., at 60 hert~). It is easily seen that the LSB requires 500 milliseconds to shift to the carry output of 30 bit shift register 156 from whence it is propagated via line 166 to the LSB position of 38 bit shift register 158. Again, it requires 1/60 second to shift to each succeeding bit position of 38 bit shift register 158.
It would take an additional 633 milliseconds for the set bit to shift the entire length of 38 bit shift register 158. This provides a total time of 1,133 seconds to shift the entire combined length of 30 bit shift register 156 and 38 bit shift register 158. The m~ximllm escape interval for the system is therefore 1,133 seconds, which corresponds to a heart rate of 52.9 beats per minute.
The output of each of thc 3S bit positions of 38 bit shift register 158 is supplied via cable 16~ to 3S x 1 ~IUX 162. By selecting the desired one of the 38 bit positions any one of 38 different escape intervals may be provided between 500 milliseconds (corresponding -to 120 beats per minute) and 1.133 milliseconds ~corresponding to 52.9 beats per minute) in 1/60 second intervals. Of course, the rate of the clock signal may be increased to achieve greater resolution if required. Similarly, the length of 38 bit shift register 158 may be changed and/or the length of 30 bit shift register 156 changed to change the range of selectable escape intervals.
Common monolithic CMOS parts are used to fabricate 38 x 1 MUX 162.
A six bit inpu~ received from six bit latch 160 via line 161 selects one of the 38 bit positions of 38 blt shift register 158 and thus determines the escape interval. If the LSB entered into 30 bit shift register 156 reaches the selected one of the 38 bit positions of 38 bit shift register 158, 38 x 1 MUX
162 outputs the pulse enable signal via line 34. Referring again to Figure 2, it is seen that this results in the output of a stimulating pulse by driver 26.
To ensure a m;n; Im rate based upon the r~ escape interval~ the carry output of 38 bit shift register 158 may be "ORED" wi~h line 3~. ~his is an optional safety measure.
Referring again to Figure 3, selection by 38 x 1 MUX 162 is made by the six bit contents of six bit latch 160 which simply holds the current escape interval selector as received from sensor processing 30. A single common monolithic CMOS part is available to implement six bit latch 160.
Two control signals are required by six bit latch 160 as received by cable 32a. A first one of these signals clears the contents of six bit _ g _ 3~
latch 160 ancl a seconcl one is delayed and enables *he six bit quantity on cable 32b to be latched into six bit latch 160.
Figure 4 is a detailed schematic view of sensor processing 30.
The analog sensor information is received from sensor 12 via line 14. ~s in ~Yirt7feld et al. this is simply a signal having a voltage that is proportional to the percentage of concentration of molecular oxygen in the intraca-rdiac venous blood. Amp 172 processes the analog signal and scales it for input to six bit A/D 176 via line 182~ The processed analog signal is converted by six bit A/D 176 into a digital signal which is transmitted via cable 32b to six bit latch 160. The data ready output signal is supplied via one conductor of cable 32a to clear six bit latch 160. The data ready signal is delayed by delay 178 and sent vi,a the other conductor of cable 32a to enable the six bit data into six bit latch 160. Clock 174 supplies the convert signal to six bit A/D 176. Clock 174 may have a very low rate (i.e.l a fraction of one hertz) as the measurable changes in blood oxygen level occur slowly relative to the conversion time of six bit A/D 176 and the resulting escape interval. ~ixed rate oscillator 112 or a submultiple thereof may be substituted for clock 174, but the asynchrony of a separate clock 174 is probably not detrimental and requires fewer components.
Figure 5 is an alternate embodiment of the present invention as incorporated in a two-chamber pacing system. The elements o~ sensor processing 30, sensor 12, electrode 18, demand logic 106 and fixed rate oscillator 112 are identical to the corresponding elements of the single chamber system and function as discussed above. Driver (v) 26 is also identical to the driver 26 of the single chamber system.
Sense amp 102 of the single chamber systeni is replaced by sense J~
amp ~p) 102a l~hich is coupled via line 104a to an electrode in atrium 22. In this way sense amp 102a monitors the atrial activity rather than the ventricular activity mollitored by sense amp 102 in the single chamber system ~see also Figure 2). ThereforeJ sense amp 102a (p) generates a p-wave sensed signal which is transferred to demand logic 106 via line 108~ whenever atrium 22 is naturally paced. Sense amp ~p) 102a is similar to sense amp 102 except for the enhanced sensitivity as is commonly known in the art for p-wave sense amplifiers.
As with the single chamber system~ demand logic 106 generates a pulse enab.e signal whenever the escape interval period has been reached as explained above. However, in this embodiment, the escape interval is measured between p-waves rather than between r-waves. Therefore a delay is supplied by A-V delay 202 to stimulate the normal atrial-to-ventricular propagation delay. This may be a fixed delay which is easily accomplished or may be a delay which is related to the pacing rate ~i.e., the inverse of the escape interval) as is also known in the art, Atrium 22 may also be artifically stimulated using driver ~A) 204 and conductor 206. This option provides an effective therapy for combined intermittent sinus-atrial block, sick sinus syndrome, sinus bradycardia, and atrial-ventricular block. The optional driver ~A) 204 improves hemodynamic performance by stimulating a synchronized atrial kick.
Other configurations can be readily constructed using the teachings found herein. For example, driver ~V) 26 may be deleted with only driver ~A) 204 in use. This configuration would readily treat intermittent sinus-atrial block or sick sinus syndrome in a patient having normal atrial-ventricular conduction.
Figure 6a is a table showing the effective mini 1~ heart rate in beats per minute correspond;ng to various selectecl bit positions of 30 bit shift register 156 and 38 bit shift register 158 ~with the total cumulative number of bit positions shown). The m~ m number of bit positions permitted by the embodiment of demand logic 106 shown in Figure 3 is 68. However, the table of Figure 6a is extended to 78 bit positions to show the e-ffect of extending 3~ bit shift register 158 to ~8 bits.
Figure 6b shows the relationship between a given level of molecular oxygen in the intracardiac venous blood and the output required of six bit A/D
176 to six bit latch 160. This result is obtained by adjusting the bias of amp 172 to provide a zero voltage input to six bit A/D 176 for an oxygen level of 60% of saturation. The gain of amp 172 is adjusted to drive six bit A/D
176 to approximately one-half of its m~imllm value for an oxygen level o-f 70% of saturation. As can be seen, therefore, a five bit A/D conversion is sufficient for the chosen system resolution~ However~ six bit devices are more commonly available. The total measured range of interest in oxygen level is between 60% and 70%. Because of the components chosen, this provides an escape interval range corresponding to 52.~ to 120 beats per minute. The system is self-limiting to remain within this range. The ideal relationship of saturation levels to escape interval can vary from patient to patient, and is preferably programmable using an external device. Support may be readily found in the current literature to permit determination of other effective relationships.
Claims (8)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A body implantable stimulator for body tissue comprising:
means for measuring a physiological parameter;
means for monitoring electrical activity in said body tissue;
means responsively coupled to said measuring means for computing a variable time interval based upon said physiological parameter as measured by said measuring means, and means responsively coupled to said monitoring means and said computing means for generating an electrical stimulation pulse if said monitoring means does not sense a predetermined electrical event during said variable time interval.
means for measuring a physiological parameter;
means for monitoring electrical activity in said body tissue;
means responsively coupled to said measuring means for computing a variable time interval based upon said physiological parameter as measured by said measuring means, and means responsively coupled to said monitoring means and said computing means for generating an electrical stimulation pulse if said monitoring means does not sense a predetermined electrical event during said variable time interval.
2, A body implantable stimulator according to Claim 1 wherein said monitoring means further comprises:
a sense amplifier.
a sense amplifier.
3. A body implantable stimulator according to Claim 2 wherein said physiological parameter is molecular oxygen level in venous blood.
4. A body implantable lead according to Claim 1, 2, or 3 wherein said predetermined electrical event further comprises an R-wave.
5. A body implantable lead according to Claim 1, 2 or 3 wherein said predetermined electrical event further comprises a P-wave,
6. A demand heart pacemaker for providing stimulating pulses to the heart at a predetermined rate in the absence of naturally occurring heartbeats comprising:
sensing means for sensing naturally occurring heart signals and generating a reset signal;
pulse generator means for generating stimulating pulses at a minimum pacing rate, including timing means for providing each stimulating pulse separated by an escape interval corresponding to the pacing rate and reset means responsive to a reset signal for resetting said timing means and restarting the escape interval;
means for measuring a physiological parameter indicative of the level of cardiac output demanded by the patient's body and for providing an escape interval modifying signal; and means responsive to the escape interval modifying signal for adjusting the escape interval to provide pacing pulses on demand at a minimum rate correlated to the cardiac output requirements of the patient.
sensing means for sensing naturally occurring heart signals and generating a reset signal;
pulse generator means for generating stimulating pulses at a minimum pacing rate, including timing means for providing each stimulating pulse separated by an escape interval corresponding to the pacing rate and reset means responsive to a reset signal for resetting said timing means and restarting the escape interval;
means for measuring a physiological parameter indicative of the level of cardiac output demanded by the patient's body and for providing an escape interval modifying signal; and means responsive to the escape interval modifying signal for adjusting the escape interval to provide pacing pulses on demand at a minimum rate correlated to the cardiac output requirements of the patient.
7. A demand heart pacemaker according to Claim 6 wherein said adjusting means further comprises means for decreasing the escape interval.
8. A demand heart pacemaker according to Claim 6 or 7 wherein said adjusting means further comprises means for increasing the escape interval.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/323,507 US4467807A (en) | 1981-11-23 | 1981-11-23 | Rate adaptive demand pacemaker |
US323,507 | 1981-11-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1192961A true CA1192961A (en) | 1985-09-03 |
Family
ID=23259494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000416050A Expired CA1192961A (en) | 1981-11-23 | 1982-11-22 | Rate adaptive demand pacemaker |
Country Status (6)
Country | Link |
---|---|
US (1) | US4467807A (en) |
AU (1) | AU556760B2 (en) |
CA (1) | CA1192961A (en) |
DE (1) | DE3243094A1 (en) |
FR (1) | FR2516797B1 (en) |
NL (1) | NL8204532A (en) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4535774A (en) * | 1983-06-30 | 1985-08-20 | Medtronic, Inc. | Stroke volume controlled pacer |
US4543955A (en) * | 1983-08-01 | 1985-10-01 | Cordis Corporation | System for controlling body implantable action device |
FR2550095B1 (en) * | 1983-08-02 | 1986-09-26 | Brehier Jacques | METHOD FOR CONTROLLING A HEART STIMULATOR AND PROBE FOR CARRYING OUT THE METHOD |
US4527568A (en) * | 1983-12-27 | 1985-07-09 | Vitafin N.V. | Dual chamber pacer with alternative rate adaptive means and method |
EP0148486B1 (en) * | 1984-01-10 | 1993-03-24 | Vitatron Medical B.V. | Improved rate adaptive pacemaker apparatus |
DE3422913A1 (en) * | 1984-06-20 | 1986-01-02 | Siemens AG, 1000 Berlin und 8000 München | CONTROL CIRCUIT FOR ADJUSTING THE STIMULATION FREQUENCY OF A PACEMAKER TO THE STRESS OF A PATIENT |
FR2566276B1 (en) * | 1984-06-21 | 1988-07-08 | Medtronic Bv | DIAPHRAGMATIC STIMULATION METHOD AND APPARATUS |
DE3428975A1 (en) * | 1984-08-06 | 1986-02-13 | Michael S. 8113 Kochel Lampadius | BREATH-CONTROLLED HEART PACEMAKER |
DE3429596A1 (en) * | 1984-08-10 | 1986-02-20 | Siemens AG, 1000 Berlin und 8000 München | DEVICE FOR THE PHYSIOLOGICAL FREQUENCY CONTROL OF A PACEMAKER PROVIDED WITH A PICTURE ELECTRODE |
US4686988A (en) * | 1984-10-19 | 1987-08-18 | Sholder Jason A | Pacemaker system and method for measuring and monitoring cardiac activity and for determining and maintaining capture |
US4860751A (en) * | 1985-02-04 | 1989-08-29 | Cordis Corporation | Activity sensor for pacemaker control |
EP0225839B1 (en) * | 1985-09-17 | 1993-12-01 | BIOTRONIK Mess- und Therapiegeräte GmbH & Co Ingenieurbüro Berlin | Heart pacemaker |
DE3650261D1 (en) * | 1985-09-17 | 1995-04-13 | Biotronik Mess & Therapieg | Pacemaker. |
DE3689347D1 (en) * | 1985-09-17 | 1994-01-13 | Biotronik Mess & Therapieg | Pacemaker. |
DE3688577D1 (en) * | 1985-09-17 | 1993-07-22 | Biotronik Mess & Therapieg | HEART PACEMAKER. |
DE3535517A1 (en) * | 1985-10-04 | 1987-04-09 | Siemens Ag | Atrial controlled pacemaker |
DE3535543A1 (en) * | 1985-10-04 | 1987-04-09 | Siemens Ag | Atrial controlled pacemaker |
DE3541598A1 (en) * | 1985-11-25 | 1987-11-19 | Alt Eckhard | LOAD-RELATED FREQUENCY VARIABLE HEART PACEMAKER |
US4791935A (en) * | 1986-08-15 | 1988-12-20 | Medtronic, Inc. | Oxygen sensing pacemaker |
US4730389A (en) * | 1986-08-15 | 1988-03-15 | Medtronic, Inc. | Method for fabrication of an implantable hermetic transparent container |
US4813421A (en) * | 1986-08-15 | 1989-03-21 | Medtronic, Inc. | Oxygen sensing pacemaker |
EP0257954B1 (en) * | 1986-08-15 | 1993-06-16 | Medtronic, Inc. | Oxygen sensing pacemaker |
US4807629A (en) * | 1986-08-15 | 1989-02-28 | Medtronic, Inc. | Oxygen sensing pacemaker |
FR2604908B1 (en) * | 1986-10-13 | 1990-06-22 | Saint Nicolas Cie Financiere | METHOD FOR ADJUSTING AN IMPLANTABLE HEART STIMULATOR ACCORDING TO THE EFFORT OF THE STIMULATOR CARRIER PATIENT, IMPLANTABLE HEART STIMULATOR AND EXTERNAL PROGRAMMER FOR CONTROLLING AN ADJUSTABLE IMPLANTABLE HEART STIMULATOR |
US4827933A (en) * | 1986-10-30 | 1989-05-09 | Telectronics N.V. | Apparatus and method for adjusting heart/pacer rate relative to cardiac pO2 obtain a required cardiac output |
US4903701A (en) * | 1987-06-05 | 1990-02-27 | Medtronic, Inc. | Oxygen sensing pacemaker |
US4750495A (en) * | 1987-06-05 | 1988-06-14 | Medtronic, Inc. | Oxygen sensing pacemaker |
US4791931A (en) * | 1987-08-13 | 1988-12-20 | Pacesetter Infusion, Ltd. | Demand pacemaker using an artificial baroreceptor reflex |
US4967748A (en) * | 1987-10-06 | 1990-11-06 | Leonard Bloom | O2 level responsive system for and method of treating a malfunctioning heart |
US4856523A (en) * | 1987-10-08 | 1989-08-15 | Siemens-Pacesetter, Inc. | Rate-responsive pacemaker with automatic mode switching and/or variable hysteresis rate |
EP0326629B2 (en) * | 1988-02-01 | 2003-09-17 | St. Jude Medical AB | Pacer with a hysteresis function |
US4945909A (en) * | 1989-06-06 | 1990-08-07 | Cook Pacemaker Corporation | Pacemaker with activity-dependent rate limiting |
US5052388A (en) * | 1989-12-22 | 1991-10-01 | Medtronic, Inc. | Method and apparatus for implementing activity sensing in a pulse generator |
US5024222A (en) * | 1990-02-21 | 1991-06-18 | Siemens-Pacesetter, Inc. | Hemodynamically rate responsive pacemaker and method of automatically adjusting the escape and A-V intervals |
US5052389A (en) * | 1990-07-26 | 1991-10-01 | Cook Pacemaker Corporation | Low-power A/D converter for an implantable medical device and method of use |
US5129393A (en) * | 1990-08-14 | 1992-07-14 | Medtronic, Inc. | Dual chamber rate responsive pacemaker with variable refractory period |
US5103820A (en) * | 1990-08-14 | 1992-04-14 | Medtronic, Inc. | VDD pacemaker with selectable post-ventricular atrial refractory periods |
US5123412A (en) * | 1990-08-14 | 1992-06-23 | Medtronic, Inc. | Dual-chamber pacemaker with automatic selection of atrial refractory period |
AU1736392A (en) * | 1991-06-11 | 1992-12-17 | Raymond E. Ideker | Reduced current cardiac pacing apparatus |
US5267564A (en) * | 1991-06-14 | 1993-12-07 | Siemens Pacesetter, Inc. | Pacemaker lead for sensing a physiologic parameter of the body |
US5213098A (en) * | 1991-07-26 | 1993-05-25 | Medtronic, Inc. | Post-extrasystolic potentiation stimulation with physiologic sensor feedback |
US5243979A (en) * | 1991-11-15 | 1993-09-14 | Medtronic, Inc. | Method and apparatus for implementing activity sensing in a pulse generator |
JPH07504596A (en) * | 1992-06-30 | 1995-05-25 | メドトロニック インコーポレーテッド | Electrical medical stimulators and electrical stimulation methods |
US5330511A (en) * | 1993-01-19 | 1994-07-19 | Vitatron Medical B.V. | Dual chamber pacemaker with automatically optimized AV delay |
US5372607A (en) * | 1993-06-23 | 1994-12-13 | Medtronic, Inc. | Method and apparatus for monitoring pacemaker intervals |
DE4329898A1 (en) * | 1993-09-04 | 1995-04-06 | Marcus Dr Besson | Wireless medical diagnostic and monitoring device |
US5531771A (en) * | 1994-10-26 | 1996-07-02 | Vitatron Medical, B.V. | Dual chamber pacemaker system and method with improved switching between synchronous and asyncrhonous behavior |
US5534017A (en) | 1994-12-02 | 1996-07-09 | Vitatron Medical, B.V. | Dual chamber pacemaker system with improved response to retrograde conduction |
US5549648A (en) * | 1995-03-29 | 1996-08-27 | Vitatron Medical, B.V. | Pacemaker system and method with improved detection of end of retrograde conduction |
US6073048A (en) * | 1995-11-17 | 2000-06-06 | Medtronic, Inc. | Baroreflex modulation with carotid sinus nerve stimulation for the treatment of heart failure |
US5814085A (en) | 1996-12-19 | 1998-09-29 | Medtronic, Inc. | Rate stabilization pacemaker |
US6125290A (en) * | 1998-10-30 | 2000-09-26 | Medtronic, Inc. | Tissue overgrowth detector for implantable medical device |
US6144866A (en) * | 1998-10-30 | 2000-11-07 | Medtronic, Inc. | Multiple sensor assembly for medical electric lead |
US5902326A (en) | 1997-09-03 | 1999-05-11 | Medtronic, Inc. | Optical window for implantable medical devices |
US6125291A (en) * | 1998-10-30 | 2000-09-26 | Medtronic, Inc. | Light barrier for medical electrical lead oxygen sensor |
US6248080B1 (en) | 1997-09-03 | 2001-06-19 | Medtronic, Inc. | Intracranial monitoring and therapy delivery control device, system and method |
US6134459A (en) * | 1998-10-30 | 2000-10-17 | Medtronic, Inc. | Light focusing apparatus for medical electrical lead oxygen sensor |
US6731976B2 (en) | 1997-09-03 | 2004-05-04 | Medtronic, Inc. | Device and method to measure and communicate body parameters |
US6198952B1 (en) | 1998-10-30 | 2001-03-06 | Medtronic, Inc. | Multiple lens oxygen sensor for medical electrical lead |
US6163723A (en) * | 1998-10-22 | 2000-12-19 | Medtronic, Inc. | Circuit and method for implantable dual sensor medical electrical lead |
US20030040665A1 (en) * | 1999-05-28 | 2003-02-27 | E-Monitors, Inc. | Systems and methods of pH tissue monitoring |
US6567679B1 (en) | 1999-05-28 | 2003-05-20 | E-Monitors, Inc. | Method of using a pH tissue monitor |
US6449510B1 (en) | 2000-04-27 | 2002-09-10 | Medtronic, Inc. | Method and system for operating an implantable medical device |
US6708062B2 (en) | 2001-10-30 | 2004-03-16 | Medtronic, Inc. | Pacemaker having adaptive arrhythmia detection windows |
US6731983B2 (en) | 2001-10-30 | 2004-05-04 | Medtronic, Inc. | Pacemaker having adaptive arrhythmia detection windows |
US7139613B2 (en) | 2002-09-25 | 2006-11-21 | Medtronic, Inc. | Implantable medical device communication system with pulsed power biasing |
US7013178B2 (en) | 2002-09-25 | 2006-03-14 | Medtronic, Inc. | Implantable medical device communication system |
US7136704B2 (en) | 2003-04-16 | 2006-11-14 | Alfred E. Mann Foundation For Scientific Research | Blood oxygen monitoring system and a lead therefor |
US7463562B2 (en) * | 2003-04-30 | 2008-12-09 | Samsung Electronics Co., Ltd. | Method of recording temporary defect list on write-once recording medium, method of reproducing the temporary defect list, recording and/or reproducing apparatus, and the write-once recording medium |
US6891229B2 (en) * | 2003-04-30 | 2005-05-10 | Freescale Semiconductor, Inc. | Inverted isolation formed with spacers |
US6944488B2 (en) * | 2003-04-30 | 2005-09-13 | Medtronic, Inc. | Normalization method for a chronically implanted optical sensor |
US20050107833A1 (en) | 2003-11-13 | 2005-05-19 | Freeman Gary A. | Multi-path transthoracic defibrillation and cardioversion |
US7239915B2 (en) * | 2003-12-16 | 2007-07-03 | Medtronic, Inc. | Hemodynamic optimization system for biventricular implants |
US7286884B2 (en) | 2004-01-16 | 2007-10-23 | Medtronic, Inc. | Implantable lead including sensor |
US7493174B2 (en) * | 2004-09-23 | 2009-02-17 | Medtronic, Inc. | Implantable medical lead |
US7512431B2 (en) * | 2005-09-13 | 2009-03-31 | Medtronic, Inc. | Normalization method for a chronically implanted optical sensor |
US7647095B2 (en) * | 2006-03-31 | 2010-01-12 | Medtronic, Inc. | Method and apparatus for verifying a determined cardiac event in a medical device based on detected variation in hemodynamic status |
US7962202B2 (en) * | 2006-03-31 | 2011-06-14 | Medtronic, Inc. | Method and apparatus for verifying a determined cardiac event in a medical device based on detected variation in hemodynamic status |
US8170636B2 (en) | 2007-06-05 | 2012-05-01 | Medtronic, Inc. | Optical sensor confidence algorithm |
US8290557B2 (en) * | 2007-12-12 | 2012-10-16 | Medtronic, Inc. | Implantable optical sensor and method for use |
US8216134B2 (en) | 2007-12-12 | 2012-07-10 | Medtronic, Inc. | Implantable optical sensor and method for manufacture |
US8275432B2 (en) * | 2007-12-12 | 2012-09-25 | Medtronic, Inc. | Implantable optical sensor and method for manufacture |
US8165676B2 (en) | 2007-12-21 | 2012-04-24 | Medtronic, Inc. | Optical sensor and method for detecting a patient condition |
US8452402B2 (en) * | 2008-04-23 | 2013-05-28 | Medtronic, Inc. | Optical sensing device for use in a medical device |
US8275435B2 (en) * | 2009-01-22 | 2012-09-25 | Medtronic, Inc. | Co-location of emitters and detectors and method of operation |
WO2010144670A1 (en) * | 2009-06-10 | 2010-12-16 | Medtronic, Inc. | Device and method for monitoring of absolute oxygen saturation and tissue hemoglobin concentration |
US8463346B2 (en) * | 2009-06-10 | 2013-06-11 | Medtronic, Inc. | Absolute calibrated tissue oxygen saturation and total hemoglobin volume fraction |
US8352008B2 (en) * | 2009-06-10 | 2013-01-08 | Medtronic, Inc. | Active noise cancellation in an optical sensor signal |
WO2010144667A1 (en) * | 2009-06-10 | 2010-12-16 | Medtronic, Inc. | Tissue oxygenation monitoring in heart failure |
WO2010144648A1 (en) * | 2009-06-10 | 2010-12-16 | Medtronic, Inc. | Shock reduction using absolute calibrated tissue oxygen saturation and total hemoglobin volume fraction |
US20110066017A1 (en) * | 2009-09-11 | 2011-03-17 | Medtronic, Inc. | Method and apparatus for post-shock evaluation using tissue oxygenation measurements |
WO2011093914A1 (en) * | 2010-01-29 | 2011-08-04 | Medtronic, Inc. | Optical sensor for medical device |
US8396563B2 (en) | 2010-01-29 | 2013-03-12 | Medtronic, Inc. | Clock synchronization in an implantable medical device system |
US8548543B2 (en) | 2010-10-29 | 2013-10-01 | Medtronic, Inc. | Symmetrically packaged optical sensors for implantable medical devices |
EP2570143B1 (en) * | 2011-09-14 | 2014-01-15 | BIOTRONIK SE & Co. KG | Implantable cardiac therapy device |
BR112015012954A2 (en) * | 2012-12-07 | 2017-07-11 | Koninklijke Philips Nv | electrostimulation device to stimulate a user with one or more pacing patterns through one or more electrodes, method on an electrostimulation device to provide a user with a notification signal using an electrostimulation device and method on a device electrostimulation to improve a user's mobility |
US9878080B2 (en) | 2014-01-14 | 2018-01-30 | CardioFlow Technologies, LLC | Apparatus and methods for optimizing intra cardiac filling pressures, heart rate, and cardiac output |
US10195441B2 (en) | 2015-05-30 | 2019-02-05 | CardioFlow Technologies, LLC | Apparatus and methods for optimizing intra-cardiac filling pressures through controlled regurgitation |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3648707A (en) * | 1969-07-16 | 1972-03-14 | Medtronic Inc | Multimode cardiac paces with p-wave and r-wave sensing means |
US4052991A (en) * | 1970-03-24 | 1977-10-11 | Fred Zacouto | Method of stimulating the heart |
FR2082703A5 (en) * | 1970-03-24 | 1971-12-10 | Zacouto Fred | |
IT1028812B (en) * | 1975-04-24 | 1979-02-10 | Alcidi M | PERFECTED ARTIFICIAL PACEMAKER |
DE2609365A1 (en) * | 1976-03-06 | 1977-09-08 | Georg Dr Med Csapo | Heart pacemaker with frequency increasing with body's demands - is controlled by changes in blood temp. measured at heart region |
DE2717659C2 (en) * | 1977-04-21 | 1985-11-14 | Wirtzfeld, Alexander, Prof. Dr.med., 8195 Egling | Pacemaker |
FR2403775A1 (en) * | 1977-09-26 | 1979-04-20 | Zacouto Fred | Heartbeat control system detecting intracardial pressure - applies stimulation pulse within specified time after detecting peak pressure signal |
US4228803A (en) * | 1978-06-23 | 1980-10-21 | Credit Du Nord International N.V. | Physiologically adaptive cardiac pacemaker |
US4305396A (en) * | 1979-04-16 | 1981-12-15 | Vitatron Medical B.V. | Rate adaptive pacemaker and method of cardiac pacing |
US4303075A (en) * | 1980-02-11 | 1981-12-01 | Mieczyslaw Mirowski | Method and apparatus for maximizing stroke volume through atrioventricular pacing using implanted cardioverter/pacer |
US4313442A (en) * | 1980-07-21 | 1982-02-02 | Cardiac Pacemakers, Inc. | Atrial rate sensitive cardiac pacer apparatus |
DE3107128C2 (en) * | 1981-02-26 | 1984-07-05 | Heinze, Roland, Dipl.-Ing., 8000 München | Control circuit for adapting the stimulation frequency of a cardiac pacemaker to the load on a patient |
US4428378A (en) * | 1981-11-19 | 1984-01-31 | Medtronic, Inc. | Rate adaptive pacer |
-
1981
- 1981-11-23 US US06/323,507 patent/US4467807A/en not_active Expired - Lifetime
-
1982
- 1982-11-22 NL NL8204532A patent/NL8204532A/en not_active Application Discontinuation
- 1982-11-22 CA CA000416050A patent/CA1192961A/en not_active Expired
- 1982-11-22 DE DE19823243094 patent/DE3243094A1/en not_active Ceased
- 1982-11-23 FR FR8219605A patent/FR2516797B1/en not_active Expired
- 1982-11-23 AU AU90795/82A patent/AU556760B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
FR2516797B1 (en) | 1988-07-15 |
US4467807B1 (en) | 1992-06-30 |
AU556760B2 (en) | 1986-11-20 |
FR2516797A1 (en) | 1983-05-27 |
AU9079582A (en) | 1983-06-02 |
NL8204532A (en) | 1983-06-16 |
US4467807A (en) | 1984-08-28 |
DE3243094A1 (en) | 1983-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1192961A (en) | Rate adaptive demand pacemaker | |
US6208900B1 (en) | Method and apparatus for rate-responsive cardiac pacing using header mounted pressure wave transducer | |
US8275458B2 (en) | Methods and systems for optimizing cardiac pacing intervals for various physiologic factors | |
US6371922B1 (en) | Method for measuring baroreflex sensitivity and therapy optimization in heart failure patients | |
US5792208A (en) | Heart pacemaker | |
US5368040A (en) | Apparatus and method for determining a plurality of hemodynamic variables from a single, chroniclaly implanted absolute pressure sensor | |
EP1629863B1 (en) | System and method for determining optimal atrioventricular delay based on intrinsic conduction delays | |
US6459929B1 (en) | Implantable cardiac rhythm management device for assessing status of CHF patients | |
US6887207B2 (en) | Methods and apparatus for estimation of ventricular afterload based on ventricular pressure measurements | |
US4917115A (en) | Pacing system and method for physiological stimulation of the heart utilizing Doppler means | |
US5954755A (en) | Facilitated atrial pacing threshold testing | |
US6144879A (en) | Heart pacemaker | |
US5931858A (en) | Implantable device for monitoring aerobic capacity of patients | |
US7654964B1 (en) | System and method for detecting arterial blood pressure based on aortic electrical resistance using an implantable medical device | |
US7079896B1 (en) | Methods of automatically optimizing AV delay by way of monitoring the heart sound | |
WO2002053228A1 (en) | Implantable medical device for monitoring congestive heart failure | |
EP0431083A1 (en) | Pacemaker having automatic rate response adjustment. | |
Brandt et al. | Far‐field QRS complex sensing: Prevalence and timing with bipolar atrial leads | |
US4907593A (en) | Adaptation of heart pacing to physical activity | |
US7904156B2 (en) | Modulation of AV delay to control ventricular interval variability | |
US7505813B1 (en) | System and method for determining preferred atrioventricular pacing delay values based on intracardiac electrogram signals | |
ES2484940T3 (en) | Pacemaker with neurocardiogenic syncope detection and therapy using minute ventilation input | |
Mond | Rate adaptive pacing: Memories from a bygone era | |
US7177687B2 (en) | Implantable cardiac stimulator wherein AV-delay adjustment is limited during dynamic atrial overdrive | |
US6862475B1 (en) | Pediatric rate varying implantable cardiac device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEC | Expiry (correction) | ||
MKEX | Expiry |